Indoleamine 2,3-Dioxygenase Is Involved in Interferon Gamma's Anti-BKPyV Activity in Renal Cells.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
07 08 2020
Historique:
received: 10 07 2020
revised: 31 07 2020
accepted: 05 08 2020
entrez: 14 8 2020
pubmed: 14 8 2020
medline: 24 2 2021
Statut: epublish

Résumé

Reactivation of BK polyomavirus (BKPyV) infection is frequently increasing in transplant recipients treated with potent immunosuppressants and highlights the importance of immune system components in controlling viral reactivation. However, the immune response to BKPyV in general and the role of antiviral cytokines in infection control in particular are poorly understood. Here, we investigated the efficacy of interferons (IFN) alpha, lambda and gamma with regard to the BKPyV multiplication in Vero cells. Treatment with IFN-gamma inhibited the expression of the viral protein VP1 in a dose-dependent manner and decreased the expression of early and late viral transcripts. Viral inhibition by IFN-gamma was confirmed in human cells (Caki-1 cells and renal proximal tubular epithelial cells). One of the IFN-stimulated genes most strongly induced by IFN-gamma was the coding for the enzyme indoleamine 2,3 dioxygenase (IDO), which is known to limit viral replication and regulates the host immune system. The antiviral activity induced by IFN-gamma could be reversed by the addition of an IDO inhibitor, indicating that IDO has a specific role in anti-BKPyV activity. A better understanding of the action mechanism of these IFN-gamma-induced antiviral proteins might facilitate the development of novel therapeutic strategies.

Identifiants

pubmed: 32784805
pii: v12080865
doi: 10.3390/v12080865
pmc: PMC7472348
pii:
doi:

Substances chimiques

IDO1 protein, human 0
Indoleamine-Pyrrole 2,3,-Dioxygenase 0
Interferon-alpha 0
Viral Structural Proteins 0
Interferon-gamma 82115-62-6
Interferons 9008-11-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Infect Dis. 2012 Jan 1;205(1):152-61
pubmed: 21990421
Am J Transplant. 2015 Aug;15(8):2159-69
pubmed: 25808077
Am J Kidney Dis. 1995 Oct;26(4):671-3
pubmed: 7573026
Transplantation. 1999 Jan 15;67(1):103-9
pubmed: 9921805
Korean J Intern Med. 2020 Apr 03;:
pubmed: 32241081
J Innate Immun. 2015;7(5):530-44
pubmed: 25792183
J Virol. 2020 Feb 28;94(6):
pubmed: 31896595
J Virol. 2007 Jan;81(1):272-9
pubmed: 17035315
J Virol. 2007 Nov;81(21):11798-808
pubmed: 17699578
Clin Transplant. 2019 Sep;33(9):e13528
pubmed: 30859620
J Immunol. 1999 Jan 15;162(2):957-64
pubmed: 9916720
Nat Rev Immunol. 2004 Oct;4(10):762-74
pubmed: 15459668
J Virol. 2017 Apr 28;91(10):
pubmed: 28250129
J Interferon Res. 1987 Oct;7(5):429-38
pubmed: 2445832
Virol J. 2009 Jun 03;6:70
pubmed: 19493343
Microbes Infect. 2004 Jul;6(9):806-12
pubmed: 15374002
J Leukoc Biol. 2019 Oct;106(4):933-942
pubmed: 31091352
J Virol. 2004 Mar;78(5):2632-6
pubmed: 14963171
J Virol. 2005 Jun;79(12):7768-76
pubmed: 15919929
Transpl Immunol. 2015 Oct;33(2):69-77
pubmed: 26002283
Mol Cell Biol. 2006 Mar;26(5):1888-97
pubmed: 16479007
Viruses. 2019 Feb 19;11(2):
pubmed: 30791409
Transplantation. 1999 Mar 27;67(6):918-22
pubmed: 10199744
mBio. 2016 Jul 05;7(4):
pubmed: 27381292
J Leukoc Biol. 2012 Apr;91(4):657-66
pubmed: 22301793
Antiviral Res. 2015 Jun;118:93-102
pubmed: 25823619
Viral Immunol. 2005;18(4):722-9
pubmed: 16359238
J Virol. 2011 Jan;85(2):1048-57
pubmed: 21084489
Am J Transplant. 2011 Nov;11(11):2443-52
pubmed: 21831150

Auteurs

Tony Fiore (T)

UR4294, Infectious Agents, Resistance and Chemotherapy, University Health Research Center, University of Picardie Jules Verne, F-80054 Amiens, France.

Elodie Martin (E)

UR4294, Infectious Agents, Resistance and Chemotherapy, University Health Research Center, University of Picardie Jules Verne, F-80054 Amiens, France.

Véronique Descamps (V)

UR4294, Infectious Agents, Resistance and Chemotherapy, University Health Research Center, University of Picardie Jules Verne, F-80054 Amiens, France.
Department of Virology, Amiens University Hospital, F-80000 Amiens, France.

Etienne Brochot (E)

UR4294, Infectious Agents, Resistance and Chemotherapy, University Health Research Center, University of Picardie Jules Verne, F-80054 Amiens, France.
Department of Virology, Amiens University Hospital, F-80000 Amiens, France.

Virginie Morel (V)

UR4294, Infectious Agents, Resistance and Chemotherapy, University Health Research Center, University of Picardie Jules Verne, F-80054 Amiens, France.
Department of Virology, Amiens University Hospital, F-80000 Amiens, France.

Lynda Handala (L)

UR4294, Infectious Agents, Resistance and Chemotherapy, University Health Research Center, University of Picardie Jules Verne, F-80054 Amiens, France.
Department of Virology, Amiens University Hospital, F-80000 Amiens, France.

Fatima Dakroub (F)

UR4294, Infectious Agents, Resistance and Chemotherapy, University Health Research Center, University of Picardie Jules Verne, F-80054 Amiens, France.

Sandrine Castelain (S)

UR4294, Infectious Agents, Resistance and Chemotherapy, University Health Research Center, University of Picardie Jules Verne, F-80054 Amiens, France.
Department of Virology, Amiens University Hospital, F-80000 Amiens, France.

Gilles Duverlie (G)

UR4294, Infectious Agents, Resistance and Chemotherapy, University Health Research Center, University of Picardie Jules Verne, F-80054 Amiens, France.
Department of Virology, Amiens University Hospital, F-80000 Amiens, France.

François Helle (F)

UR4294, Infectious Agents, Resistance and Chemotherapy, University Health Research Center, University of Picardie Jules Verne, F-80054 Amiens, France.

Catherine François (C)

UR4294, Infectious Agents, Resistance and Chemotherapy, University Health Research Center, University of Picardie Jules Verne, F-80054 Amiens, France.
Department of Virology, Amiens University Hospital, F-80000 Amiens, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH